| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
American Society of Hematology 2019 guidelines for immune thrombocytopenia
|
Neunert, Cindy
|
|
|
3 |
23 |
p. 3829-3866
|
artikel
|
| 2 |
American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients
|
Anderson, David R.
|
|
|
3 |
23 |
p. 3898-3944
|
artikel
|
| 3 |
American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease
|
Liem, Robert I.
|
|
|
3 |
23 |
p. 3867-3897
|
artikel
|
| 4 |
Amplification and overexpression of E2 ubiquitin conjugase UBE2T promotes homologous recombination in multiple myeloma
|
Alagpulinsa, David A.
|
|
|
3 |
23 |
p. 3968-3972
|
artikel
|
| 5 |
A novel immature natural killer cell subpopulation predicts relapse after cord blood transplantation
|
Li, Li
|
|
|
3 |
23 |
p. 4117-4130
|
artikel
|
| 6 |
Computational analysis of continuous body temperature provides early discrimination of graft-versus-host disease in mice
|
He, Kuang
|
|
|
3 |
23 |
p. 3977-3981
|
artikel
|
| 7 |
Editorial Board
|
|
|
|
3 |
23 |
p. i
|
artikel
|
| 8 |
End points for sickle cell disease clinical trials: patient-reported outcomes, pain, and the brain
|
Farrell, Ann T.
|
|
|
3 |
23 |
p. 3982-4001
|
artikel
|
| 9 |
End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings
|
Farrell, Ann T.
|
|
|
3 |
23 |
p. 4002-4020
|
artikel
|
| 10 |
Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion
|
Wienand, Kirsty
|
|
|
3 |
23 |
p. 4065-4080
|
artikel
|
| 11 |
Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone
|
Kastritis, Efstathios
|
|
|
3 |
23 |
p. 4095-4103
|
artikel
|
| 12 |
Inhibition of the mutated c-KIT kinase in AML1-ETO–positive leukemia cells restores sensitivity to PARP inhibitor
|
Nieborowska-Skorska, Margaret
|
|
|
3 |
23 |
p. 4050-4054
|
artikel
|
| 13 |
Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents
|
Aldoss, Ibrahim
|
|
|
3 |
23 |
p. 4043-4049
|
artikel
|
| 14 |
Leukocytosis and thrombosis in polycythemia vera: can clinical trials settle the debate?
|
Barbui, Tiziano
|
|
|
3 |
23 |
p. 3951-3952
|
artikel
|
| 15 |
Molecular features of a large cohort of primary central nervous system lymphoma using tissue microarray
|
Villa, Diego
|
|
|
3 |
23 |
p. 3953-3961
|
artikel
|
| 16 |
Oral Bruton tyrosine kinase inhibitors block activation of the platelet Fc receptor CD32a (FcγRIIA): a new option in HIT?
|
Goldmann, Luise
|
|
|
3 |
23 |
p. 4021-4033
|
artikel
|
| 17 |
Patients with FLT3-mutant AML needed to enroll on FLT3-targeted therapeutic clinical trials
|
Bucy, Taylor
|
|
|
3 |
23 |
p. 4055-4064
|
artikel
|
| 18 |
PTCy ameliorates GVHD by restoring regulatory and effector T-cell homeostasis in recipients with PD-1 blockade
|
Ikegawa, Shuntaro
|
|
|
3 |
23 |
p. 4081-4094
|
artikel
|
| 19 |
Resolution of secondary hemophagocytic lymphohistiocytosis after treatment with the JAK1/2 inhibitor ruxolitinib
|
Goldsmith, Scott R.
|
|
|
3 |
23 |
p. 4131-4135
|
artikel
|
| 20 |
2019 sickle cell disease guidelines by the American Society of Hematology: methodology, challenges, and innovations
|
Murad, M. Hassan
|
|
|
3 |
23 |
p. 3945-3950
|
artikel
|
| 21 |
Smooth muscle cytochrome b5 reductase 3 deficiency accelerates pulmonary hypertension development in sickle cell mice
|
Wood, Katherine C.
|
|
|
3 |
23 |
p. 4104-4116
|
artikel
|
| 22 |
Stem cell mutations can be detected in myeloma patients years before onset of secondary leukemias
|
Sridharan, Ashwin
|
|
|
3 |
23 |
p. 3962-3967
|
artikel
|
| 23 |
Stroke and myocardial infarction in hereditary thrombotic thrombocytopenic purpura: similarities to sickle cell anemia
|
Borogovac, Azra
|
|
|
3 |
23 |
p. 3973-3976
|
artikel
|
| 24 |
The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease
|
Srinagesh, Hrishikesh K.
|
|
|
3 |
23 |
p. 4034-4042
|
artikel
|
| 25 |
Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
|
Chen, Yi-Bin
|
|
|
3 |
23 |
p. 4136-4146
|
artikel
|
Tijdschrift beschrijving